Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 9, 2009, Pages 532-541

  Sugioka, Nobuyuki ^a   Haraya, Kenta ^a   Fukushima, Keizo ^a   Ito, Yukako ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Dyslipidemia; Hepatic steatosis; Nelfinavir; Pharmacokinetics; Protein binding

Indexed keywords

ATAZANAVIR; BILE ACID; GLYCOPROTEIN P; LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE ACID BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MONITORING; DYSLIPIDEMIA; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; FATTY LIVER; HUMAN IMMUNODEFICIENCY VIRUS; INTRAABDOMINAL FAT; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AREA UNDER CURVE; BILE; DIETARY FATS; DRUG MONITORING; DYSLIPIDEMIAS; FATTY LIVER; HIV PROTEASE INHIBITORS; INTESTINES; MALE; METABOLIC SYNDROME X; NELFINAVIR; OBESITY; P-GLYCOPROTEIN; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 73349087233     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.689     Document Type: Article

References (29)

1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
2. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005; 26: 394-404.
3. Vanhove GF, Gries JM, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41: 2433-2438.
4. Dorsey BD, Levin RB, McDaniel SL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37: 3443-3451.
5. Hoetelmans R, Miller V. Therapeutic drug monitoring in HIV disease. J HIV Ther 2001; 6: 65-67.
6. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41: 461-467.
7. Longer M, Shetty B, Zamansky I, Tyle P. Preformulation studies of a novel HIV protease inhibitor, AG1343. J Pharm Sci 1995; 84: 1090-1093.
8. Herforth C, Stone JA, Jayewardene AL, et al. Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization. Eur J Pharm Sci 2002; 15: 185-195.
9. Schon A, del Mar Ingaramo M, Freire E. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003; 105: 221-230.
10. Olmo M, Podzamczer D. A review of nelfinavir for the treatment of HIV infection. Expert Opin Drug Metab Toxicol 2006; 2: 285-300.
11. Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother 1999; 33: 325-339.
12. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
13. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
14. Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD. Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic- pharmacodynamic analysis. Metab Syndr Relat Disord 2007; 5: 163-173.
15. Sugioka N, Haraya K, Maeda Y, Fukushima K, Takada K. Pharmacokinetics of human immuno-deficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats. Biol Pharm Bull 2009; 32: 269-275.
16. Gao W, Kishida T, Kimura K, et al. Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16: 267-273.
17. Fukushima K, Terasaka S, Haraya K, et al. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. Biol Pharm Bull 2007; 30: 733-738.
18. Anai M, Funaki M, Ogihara T, et al. Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 1999; 48: 158-169.
19. Yoshikawa Y, Kato K, Sone H, Takada K. Development and evaluation of Noncompartmental Pharmacokinetic analysis program WinHARMONY using Visual BASIC language having a function of an automatic recognition of terminal elimination phase of plasma drug concentration vs. time profile. Jpn J Clin Pharmacol 1998; 29: 475-487.
20. Simon N, Dailly E, Combes O, et al. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 1998; 45: 173-175.
21. Schuhmacher J, Buhner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2000; 89: 1008-1021.
22. Monks A, Richens A. Plasma protein binding interaction between valproic acid and palmitic acid in vitro [proceedings]. Br J Clin Pharmacol 1978; 6: 448P.
23. Bickel MH. Factors affecting the storage of drugs and other xenobiotics in adipose tissue. In Advances in Drug Research, Testa B, Meyer UA (eds), vol 25. Academic Press: London, 1994; 55-86.
24. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231.
25. Shibata N, Gao W, Okamoto H, et al. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci 2002; 91: 680-689.
26. Ijaz S, Yang W, Winslet MC, Seifalian AM. The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis. Microvasc Res 2005; 70: 129-136.
27. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999; 68: 780-784.
28. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28: 410-416.
29. Brocks DR, Ala S, Aliabadi HM. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 2006; 27: 7-16.